Update on the price control power struggle
I previously posted how price controls and compulsory licensing give buyers more power … for a price and Abbott’s spat […]
I previously posted how price controls and compulsory licensing give buyers more power … for a price and Abbott’s spat […]
Coming soon, a new biotechnology magazine from The Scientist called Biotech 360. I’ve been asked to compile a list of
In response to Thailand’s decision to issue compulsory licenses for Kaletra and for Plavix, effectively bypassing their patents by purchasing
Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report
I’ll be giving a talk at UC Davis from April 19-20th and UNC Chapel Hill from May 16-17th. If you’re
Following up on the success of “Building Biotechnology” (www.BuildingBiotechnology.com), I’m in the late stages of assembling a more advanced follow-up
Write a chapter for my book on Advanced Topics in Biotechnology Business Development Read Post »
Genentech is investing $140mm in a new biologic manufacturing plant in Singapore. The first commercial-scale microbial fermentation plant in Singapore,
I touched briefly on the Medimmune v. Genentech case in a previous Carnival of Biotechnology, but I didn’t go into
The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian! For more information, see the Carnival of
Just came across an article on diabetics going to Mexico to receive pig xenotransplants. Unlike other forms of medical tourism,